

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
May 18, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

May 18, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b): 82-\_\_\_\_\_

TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in  
accordance with the provisions of the European Commission's regulation no  
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

## Edgar Filing: NOVO NORDISK A S - Form 6-K

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 11 May 2009, the following transactions have been made under the programme:

|                                    | NUMBER OF<br>SHARES | AVERAGE PURCHASE<br>PRICE | TRANSACTION<br>VALUE, DKK |
|------------------------------------|---------------------|---------------------------|---------------------------|
| ACCUMULATED, LAST<br>ANNOUNCEMENT  | 5,782,182           |                           | 1,594,199,578             |
| 11 May 2009                        | 90,000              | 270.82                    | 24,373,800                |
| 12 May 2009                        | 90,000              | 273.70                    | 24,633,000                |
| 13 May 2009                        | 95,000              | 280.40                    | 26,638,000                |
| 14 May 2009                        | 75,000              | 277.61                    | 20,820,750                |
| 15 May 2009                        | 90,000              | 278.54                    | 25,068,591                |
| ACCUMULATED UNDER<br>THE PROGRAMME | 6,132,182           |                           | 1,690,665,128             |

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 17,600 B shares in the period from 11 May to 15 May. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 30,932,425 treasury shares, corresponding to 4.9% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

The Annual General Meeting of Novo Nordisk A/S, which was held on 18 March 2009, approved a 2.2% reduction in the total share capital by cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal value of DKK 14,000,000. After the legal implementation of the share capital reduction, which is expected to take place after expiry of the legal notice period in June 2009, Novo Nordisk's share capital will amount to DKK 620,000,000 divided into an A share capital of DKK 107,487,200 and a B share capital of DKK 512,512,800. Taking into account the expected cancellation Novo Nordisk would currently own 2.7% of such reduced share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

Media:

Outside North America:  
Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

Investors:

Outside North America:  
Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

## Edgar Filing: NOVO NORDISK A S - Form 6-K

In North America:  
Sean Clements  
Tel: (+1) 609 514 8316  
secl@novonordisk.com

In North America:  
Hans Rommer  
Tel: (+1) 609 919 7937  
hrmm@novonordisk.com

Company Announcement no 28 / 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: May 18, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer